|
 Fujirebio, a subsidiary of Japanese diagnostics and laboratory
testing service provider Miraca Holdings, last month applied for
government approval for its antigen kit.
Antigen tests scan for proteins found on or inside a virus, and
typically test a sample taken from the nasal cavity using swabs. The
tests can detect the virus quickly but produce false negatives at a
higher rate than the currently dominant PCR, or polymerase chain
reaction, tests.
"It is difficult to keep track of all those who are infected with
PCR tests alone," Chief Cabinet Secretary Yoshihide Suga told a
regular news conference on Tuesday.
"We will try and get a good grasp of the infection situation with
various measures such as antigen tests and antibody tests."
Japan has reported about 16,680 confirmed infections, including 712
from the cruise ship previously quarantined in Yokohama, and 670
deaths to date, public broadcaster NHK said.
Although those tallies are relatively low given its population of
126 million, critics say the low rate of testing has made it
difficult to trace the virus, which has led to a series of
in-hospital infections, crippling some facilities.
Japan has conducted 188 PCR tests per 100,000 people, versus 3,159
in Italy and 3,044 in Germany, data from a panel of medical experts
advising the government showed.
[to top of second column] |
Faced with criticism, Japan eased access to PCR tests this month.
Antigen tests, once approved, will likely supplement PCR tests,
Health Minister Katsunobu Kato has said.
It takes about 30 minutes to get a result with Fujirebio's
palm-sized antigen test kit, compared with four to six hours for a
PCR test, the health ministry said in a statement.
Fujirebio can produce 200,000 kits per week, roughly on par with the
number of PCR tests conducted in April in Japan.
Demand for rapid testing kits has surged with governments scrambling
to contain the pandemic that has infected more than 4 million people
worldwide and killed over 285,000.
The United States has approved its first antigen kit, made by Quidel
Corp, while Malaysia has approved the use of rapid test kits from
South Korea.
Japan has approved Gilead Sciences' remdesivir as a treatment for
COVID-19, making it the country's first authorized drug to tackle
the disease caused by the novel coronavirus.
Prime Minister Shinzo Abe's government aims to approve by the end of
the month Fujifilm Holdings Corp's anti-flu drug Avigan as a
treatment for COVID-19.
(Reporting by Kiyoshi Takenaka; Editing by Edwina Gibbs and Himani
Sarkar)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
